Please note that this content was created in 2018. In the time since this material was posted, there may have been additional developments, advancements, and/or more current publications in this field.
AMP Education is constantly updating our educational offerings, and will remove or replace content that is no longer accurate. Please be sure to use the search function to find related or updated material available in our catalogue at educate.amp.org. The Training and Education Committee works with AMP Education Programs to bring you the most up-to-date and cutting-edge information on molecular pathology research, applications, and training.
This is a recording of a session from AMP Europe 2018 meeting in Rotterdam. Purchase the entire AMP Europe 2018 Recordings for a significant discount!
Many challenges exist in assaying mutational burden in cancer (TMB). This interactive session will explore how oncology can best use TMB and what diagnostic information is needed to predict response to immunotherapy.
Microsatellite Instability in Relation to PDL1 Expression and Tumor Mutational Burden in Cancer Patients
Ari M. VanderWalde, MD, MPH (Germantown, USA)
Objectives:
- Understand and describe the underlying biology and concept of tumor mutational burden (TMB).
- Understand and describe the prerequisites and specific characteristics of assays measuring TMB.
- Describe and interpret the clinical utility of TMB.
Duration: 1.00 hr
Recording Date: May 1, 2018
Last day to purchase: December 31, 2021
There are no CME/CMLE or SAMs credits available.Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
